AU2008359989A1 - Drug carriers - Google Patents

Drug carriers Download PDF

Info

Publication number
AU2008359989A1
AU2008359989A1 AU2008359989A AU2008359989A AU2008359989A1 AU 2008359989 A1 AU2008359989 A1 AU 2008359989A1 AU 2008359989 A AU2008359989 A AU 2008359989A AU 2008359989 A AU2008359989 A AU 2008359989A AU 2008359989 A1 AU2008359989 A1 AU 2008359989A1
Authority
AU
Australia
Prior art keywords
carrier
therapeutic composition
therapeutic
cationic polymeric
polymeric carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008359989A
Other languages
English (en)
Inventor
Fu Chen
Yoshiro Niitsu
Sang Van
Lei Yu
Gang Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of AU2008359989A1 publication Critical patent/AU2008359989A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008359989A 2008-07-30 2008-09-12 Drug carriers Abandoned AU2008359989A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US8496408P 2008-07-30 2008-07-30
US8497708P 2008-07-30 2008-07-30
US8494708P 2008-07-30 2008-07-30
US8495508P 2008-07-30 2008-07-30
US8496808P 2008-07-30 2008-07-30
US8493908P 2008-07-30 2008-07-30
US61/084,964 2008-07-30
US61/084,968 2008-07-30
US61/084,947 2008-07-30
US61/084,955 2008-07-30
US61/084,939 2008-07-30
US61/084,977 2008-07-30
PCT/US2008/076295 WO2010014117A1 (en) 2008-07-30 2008-09-12 Drug carriers

Publications (1)

Publication Number Publication Date
AU2008359989A1 true AU2008359989A1 (en) 2010-02-04

Family

ID=40627040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008359989A Abandoned AU2008359989A1 (en) 2008-07-30 2008-09-12 Drug carriers

Country Status (11)

Country Link
US (2) US20100028416A1 (enExample)
EP (1) EP2323693B1 (enExample)
JP (3) JP2011529492A (enExample)
KR (2) KR20110051214A (enExample)
CN (1) CN102159247A (enExample)
AU (1) AU2008359989A1 (enExample)
CA (1) CA2732412C (enExample)
ES (1) ES2657214T3 (enExample)
RU (2) RU2505315C2 (enExample)
TW (1) TW201004646A (enExample)
WO (1) WO2010014117A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358223B2 (en) * 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
JP2009221164A (ja) 2008-03-17 2009-10-01 Nitto Denko Corp 肺線維症処置剤
SI2727583T1 (sl) 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US9572886B2 (en) * 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20080312174A1 (en) * 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
WO2009036368A2 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
TWI556831B (zh) * 2008-09-12 2016-11-11 日東電工股份有限公司 纖維化疾病之造影劑
DK2509991T3 (en) 2009-12-09 2015-12-21 Nitto Denko Corp MODULATION OF HSP47 EXPRESSION
AU2011266057B2 (en) * 2010-06-17 2014-12-04 Nitto Denko Corporation Agent for treating renal fibrosis
JP5950428B2 (ja) 2010-08-05 2016-07-13 日東電工株式会社 線維化組織から正常組織を再生するための組成物
CN102652835A (zh) * 2010-12-10 2012-09-05 邹长坪 缓释高分子维甲酸
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
CN107082747B (zh) * 2011-06-08 2020-11-20 日东电工株式会社 用于定向药物输送和增强siRNA活性的化合物
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations
ES2708932T3 (es) 2011-06-21 2019-04-12 Nitto Denko Corp Agente inductor de apoptosis
US20140323550A1 (en) * 2011-11-18 2014-10-30 Nitto Denko Corporation Intestinal fibrosis treatment agent
WO2013169337A1 (en) * 2012-05-07 2013-11-14 Nitto Denko Corporation Polymer conjugates with a linker
EP2914247A4 (en) * 2012-10-30 2016-06-29 Particle Sciences Inc DRUG DELIVERY PARTICLE FORMULATIONS WITH TARGETING ELEMENTS
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
EP2989116A4 (en) * 2013-04-26 2017-01-18 Nitto Denko Corporation Reduction of endotoxins from polyanionic polymer conjugates
KR102091588B1 (ko) * 2013-05-27 2020-03-24 주식회사 바이오리더스 폴리감마글루탐산을 함유하는 점액 분산 또는 수화용 조성물
EP2823811A1 (en) * 2013-07-09 2015-01-14 OTC GmbH Targeted active release system comprising solid lipid nano-particles
CA2923035A1 (en) * 2013-09-03 2015-03-12 William Marsh Rice University Treatment of inflammatory diseases by carbon materials
US11430024B2 (en) * 2013-09-04 2022-08-30 Amos M. Cohen System and method of providing a virtual guestbook
IN2013MU03918A (enExample) * 2013-12-13 2015-09-25 Cipla Ltd
WO2015152332A1 (ja) 2014-04-02 2015-10-08 日東電工株式会社 標的化分子およびその使用
KR102256453B1 (ko) * 2014-04-07 2021-05-25 닛토덴코 가부시키가이샤 소수성 약물 전달용 신규한 폴리머계 하이드로트로프
KR20210125603A (ko) 2014-06-16 2021-10-18 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
WO2015194522A1 (ja) 2014-06-17 2015-12-23 日東電工株式会社 アポトーシス誘導剤
RU2575925C1 (ru) * 2014-11-06 2016-02-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Тетравалентные неогликоконъюгаты с углеводным разветвляющим ядром и способ их получения
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
ES2883290T3 (es) * 2015-09-15 2021-12-07 Samyang Holdings Corp Composición farmacéutica para el suministro de un fármaco aniónico
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
US11878061B2 (en) 2016-03-21 2024-01-23 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
AU2017238119A1 (en) 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
RU2019109211A (ru) 2016-09-01 2020-10-01 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции, содержащие носитель-pd-l1-связывающий агент для лечения рака
EP3510048A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Methods of treating pd-l1 expressing cancer
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2018048958A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
RU2703624C2 (ru) * 2017-11-10 2019-10-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Коаксиальные регулярные нано-мезоструктуры, способ их получения и способ получения микрокапсул из этих структур
US11590080B2 (en) 2017-12-18 2023-02-28 C.R. Bard, Inc. Drug-loaded biodegradable microbead compositions including drug-containing vesicular agents
US11607388B2 (en) 2017-12-18 2023-03-21 C.R. Bard, Inc. Drug-loaded microbead compositions, embolization compositions and associated methods
KR20200087594A (ko) * 2019-01-11 2020-07-21 한국화학연구원 레티노익산을 포함하는 미립구형 서방출 제제 및 그의 제조방법
EP4031142A1 (en) 2019-09-19 2022-07-27 Danmarks Tekniske Universitet Immune stimulating micelle composition
WO2021067914A1 (en) * 2019-10-03 2021-04-08 The Trustees Of Columbia University In The City Of New York Combination therapy for acute myeloid leukemia, myelodysplastic syndromes and other blood diseases and disorders
KR20220128568A (ko) * 2021-03-12 2022-09-21 주식회사 엑소스템텍 비타민 a로 표면개질된 엑소좀을 포함하는 간 섬유증 예방 또는 치료용 약학적 조성물

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667874A5 (fr) * 1985-12-19 1988-11-15 Battelle Memorial Institute Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments.
US5541297A (en) * 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
FR2664500B1 (fr) * 1990-07-13 1994-10-28 Lille Ii Universite Droit Sant Procede de preparation d'une lipoproteine modifiee par incorporation d'une substance active lipophile, lipoproteine modifiee ainsi obtenue et composition pharmaceutique ou cosmetique la contenant.
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
JP3631755B2 (ja) * 1994-03-23 2005-03-23 明治製菓株式会社 ポリオキシエチレン含有脂質二本鎖誘導体
US6326356B1 (en) * 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US6033849A (en) * 1995-05-26 2000-03-07 The Salk Institute For Biological Studies Method for isolation of extrachromosomal amplified genes
HUP9700322A3 (en) * 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US6183774B1 (en) * 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
SI0932399T1 (sl) * 1996-03-12 2006-10-31 Pg Txl Co Lp Vodotopna paklitakselna predzdravila
ZA972087B (en) * 1996-03-15 1997-10-24 Theratech Inc Targeting macromolecular produgs to T lymphocytes.
CA2250222A1 (en) * 1996-03-20 1997-09-25 Mien-Chie Hung Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US6566353B2 (en) * 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6683048B1 (en) * 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
AU756301B2 (en) * 1997-08-20 2003-01-09 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
US6399383B1 (en) * 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6596770B2 (en) * 2000-05-05 2003-07-22 Medinox, Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
DE69926535T2 (de) * 1998-12-18 2006-03-30 Scios Inc., Sunnyvale Behandlung von erkrankungen mit zystenbildung
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
FR2790405B1 (fr) * 1999-03-02 2001-04-20 Oreal Nanocapsules a base de polymeres dendritiques
ID30460A (id) * 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
US6319510B1 (en) * 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
US6663606B1 (en) * 1999-10-28 2003-12-16 Scimed Life Systems, Inc. Biocompatible medical devices
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
US6566385B2 (en) * 2000-01-12 2003-05-20 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SK10342002A3 (sk) * 2000-01-31 2003-12-02 Pfizer Products Inc. Pyrimidínkarboxamidy užitočné ako selektívne inhibítory izozymov PDE4
AU2001261031A1 (en) * 2000-04-17 2001-10-30 Childrens Hospital Research Foundation Inhibition of bone tumor formation using antisense cdna therapy
ES2247142T3 (es) * 2000-05-02 2006-03-01 F. Hoffmann-La Roche Ag Nuevos retinoides gamma selectivos.
US20040047910A1 (en) * 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol
US7485320B2 (en) * 2000-09-25 2009-02-03 Industrial Technology Research Institute Liposome for incorporating large amounts of hydrophobic substances
US6660034B1 (en) * 2001-04-30 2003-12-09 Advanced Cardiovascular Systems, Inc. Stent for increasing blood flow to ischemic tissues and a method of using the same
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
EP1401506A4 (en) * 2001-05-31 2005-02-16 Miravant Pharm Inc METAL TETRAPYRROLIC PHOTOSENSITIZATION AGENTS FOR PHOTODYNAMIC THERAPY
JP2005507934A (ja) * 2001-10-30 2005-03-24 ネクター セラピューティックス エイエル，コーポレイション レチノイン酸の水溶性ポリマー結合体
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20040122080A1 (en) * 2002-03-22 2004-06-24 Vivat-Hannah Valerie S Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
US6869591B2 (en) * 2002-03-26 2005-03-22 Barnes-Jewish Hospital Paramagnetic particles that provide improved relaxivity
AU2002347747A1 (en) * 2002-07-23 2004-02-09 Ardenia Investments Ltd. Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20060151574A1 (en) * 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
US20040138154A1 (en) * 2003-01-13 2004-07-15 Lei Yu Solid surface for biomolecule delivery and high-throughput assay
US8969543B2 (en) * 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US7064127B2 (en) * 2003-12-19 2006-06-20 Mount Sinai School Of Medicine Of New York University Treatment of hepatic fibrosis with imatinib mesylate
US7284401B2 (en) * 2004-01-12 2007-10-23 Boston Scientific Scimed, Inc. Stent reducing system and device
US7304045B2 (en) * 2004-10-05 2007-12-04 Hsing-Wen Sung Nanoparticles for targeting hepatoma cells
SI2727583T1 (sl) * 2004-12-22 2022-01-31 Nitto Denko Corporation Nosilec učinkovine in komplet nosilca učinkovine za zaviranje fibroze
AU2006322254B2 (en) * 2005-12-05 2012-08-02 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
JP5342834B2 (ja) * 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
WO2009036368A2 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers

Also Published As

Publication number Publication date
JP2011529492A (ja) 2011-12-08
RU2011107076A (ru) 2012-09-10
KR20140065017A (ko) 2014-05-28
RU2505315C2 (ru) 2014-01-27
JP2016104732A (ja) 2016-06-09
KR20110051214A (ko) 2011-05-17
ES2657214T3 (es) 2018-03-02
CA2732412A1 (en) 2010-02-04
JP2014129364A (ja) 2014-07-10
TW201004646A (en) 2010-02-01
CA2732412C (en) 2014-12-09
WO2010014117A1 (en) 2010-02-04
RU2013146387A (ru) 2015-04-27
US20140212474A1 (en) 2014-07-31
EP2323693A1 (en) 2011-05-25
US20100028416A1 (en) 2010-02-04
CN102159247A (zh) 2011-08-17
EP2323693B1 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
CA2732412C (en) Retinoid-targeted drug carriers
Abdellatif et al. Approved and marketed nanoparticles for disease targeting and applications in COVID-19
US8003621B2 (en) Drug carriers
Cheetham et al. Self-assembling prodrugs
Li et al. Enhanced cellular internalization and on-demand intracellular release of doxorubicin by stepwise pH-/reduction-responsive nanoparticles
JP2011513412A (ja) ポリマーパクリタキセル結合体を含む癌を治療するための薬学組成物
Shim et al. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy
WO2015099985A2 (en) Cationic materials and formulations for drug delivery
KR20100062990A (ko) 국소적 약물전달을 위한 주사용 고분자-지질 배합물
Shi et al. Intelligent “Peptide-Gathering Mechanical Arm” tames wild “Trojan-Horse” peptides for the controlled delivery of cancer nanotherapeutics
KR20170086638A (ko) 약학 조성물, 이의 제조 및 용도
Zhang et al. Virus mimetic shell-sheddable chitosan micelles for siVEGF delivery and FRET-traceable acid-triggered release
JP2022066256A (ja) ダクチノマイシン組成物並びに骨髄異形成症候群及び急性骨髄性白血病の治療方法
Zhao et al. Drug‐phospholipid conjugate nano‐assembly for drug delivery
CA2863307C (en) Retinoid-targeted drug carriers
Chhikara et al. Nanotherapeutics and HIV: Four decades of infection canvass the quest for drug development using nanomedical technologies
Chakraborty et al. Strategies for targeted delivery via structurally variant polymeric nanocarriers
HK1159504A (en) Drug carriers
CN110200920A (zh) 一种还原敏感药物组合物及其制备和应用
Dass Cyclodextrins and oligonucleotide delivery to solid tumours
Agnihotri et al. PEGylated Nanocarriers for Protein and Peptide Delivery
Stieger et al. The use of dendrimers to optimize the physicochemical and therapeutic properties of drugs
Paroha et al. treat amyotrophic lateral sclerosis Menu

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ; NIITSU, YOSHIRO; VAN, SANG;CHEN, FU; ZHAO, GANG AND YU, LEI

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application